CSPC Innovation Pharmaceutical (SHE:300765) recorded a 98% decline in attributable profit in the third quarter to 2.3 million yuan from 116.9 million yuan a year prior, a Wednesday bourse filing by parent CSPC Pharmaceutical (HKG:1093) said.
Earnings per share were 0.002 yuan in the quarter, down from 0.0838 yuan in the corresponding period of last year.
The pharmaceutical company's revenue declined by 14% to 507.1 million yuan in the three months ended Sept. 30 from 592.9 million yuan in the year-ago period.
For the nine months ended Sept. 30, attributable profit and revenue plummeted 64% and 24% to 139.3 million yuan and 1.48 billion yuan, respectively.
Shares of CSPC Innovation Pharmaceutical closed 2% higher on Wednesday, while those of CSPC Pharmaceutical closed over 1% lower.
Price (HKD): $31.23, Change: $+0.61, Percent Change: +1.99%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。